

PROMOTED BY



FONDAZIONE  
INTERNAZIONALE  
MENARINI

December

1<sup>st</sup> - 3<sup>rd</sup>, 2016

Bologna (Italy)



*International Symposium on:*

URIC ACID AND CARDIOVASCULAR DISEASE:  
BACK TO PATHOPHYSIOLOGY

PROGRAM

Salone del Podestà - Palazzo Re Enzo  
(Piazza del Nettuno, 1 - Bologna)

*Organized by*

Department of Medical and Surgical Sciences (DIMEC)  
Alma Mater Studiorum University of Bologna, Italy

Division of Renal Diseases and Hypertension University of Colorado  
Anschutz Medical Campus - Denver CO, USA



*The role of serum uric acid as a risk factor for CV disease has been extensively debated for many years without reaching a final agreement among clinicians and researchers. In particular, most of the evidence about the pathogenetic role of uric acid in CV disease have been achieved in the population of patients with severe hyperuricemia or gout, while its role in patients with mildly elevated serum levels of uric acid is only poorly recognized. Serum uric acid represents an important, independent risk factor for cardiovascular and renal disease in patients with hypertension, heart failure or diabetes. Elevated serum uric acid is highly predictive of mortality in patients with heart failure or coronary artery disease and of cardiovascular events in patients with diabetes.*

*Although the mechanism(s) by which uric acid may play a pathogenetic role in cardiovascular disease is still unclear, hyperuricemia is associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, hemorheology and aggregation. Whether a reduction in uric acid impacts CV and renal disease remains to be determined, however, recent findings from LIFE suggest the possibility that a treatment-induced decrease in serum uric acid may indeed attenuate cardiovascular risk. Clearly, randomized clinical trials are needed to investigate further the long-term cardioprotective benefits issue of reducing hyperuricemia in hypertensive patients.*

*The main purpose of the present symposium is twofold. First of all to reinforce the role of uric acid in the pathogenesis of gout and gout-related non-rheumatic diseases including renal involvement. Second to provide an updated review of the evidence supporting a possible and relevant role of (elevated) uric acid as a risk factor for cardiovascular diseases. To fulfill this goal we will present a series of comprehensive lectures mainly focused on the different aspects of the relationship between serum uric acid and cardiovascular diseases with the aim to define whether or not the increase in the amount of our knowledge about uric acid may contribute to decrease the number of major risk factors.*

*Presidents of the Meeting  
Claudio Borghi and Richard J. Johnson*

With the patronage of



**Presidents  
of the Symposium**

**Claudio Borghi**

*Department of Medical and Surgical Sciences (DIMEC)  
Alma Mater Studiorum University of Bologna  
Bologna, Italy*

**Richard J. Johnson**

*Division of Renal Diseases and Hypertension  
University of Colorado  
Anschutz Medical Campus Denver - CO, USA*

**Scientific  
Secretariat**

**Stefania Corvaglia**

*University Hospital of Bologna S. Orsola Malpighi  
Bologna, Italy*

**Arrigo F.G. Cicero**

*Alma Mater Studiorum University of Bologna  
Bologna, Italy*

**Promoted by**

**Fondazione Internazionale Menarini**

*Centro Direzionale Milanofiori  
20089 Rozzano (Milan, Italy)  
Edificio L – Strada 6  
Phone: +39 02 55308110  
Fax: +39 02 55305739  
E-mail: milan@fondazione-menarini.it  
website: www.fondazione-menarini.it*

**Organizing  
Secretariat  
and Provider  
for Italian CME  
accreditation**

**I & C s.r.l.**

*Via Andrea Costa, 202/6  
40134 Bologna (Italy)  
Tel.: +39 051 6144004  
Fax: +39 051 6142772  
E-mail: stefania.parolari@iec-srl.it*

## Thursday, December 1<sup>st</sup>, 2016 – Afternoon

### Opening ceremony

- 06.00 p.m. Welcome addresses  
**C. Borghi** (Bologna, I)
- 06.15 p.m. **MAIN LECTURE**  
**Introduction:**  
**M. H. Alderman** (New York - NY, USA)  
**E. Ambrosioni** (Bologna, I)  
**R. J. Johnson** (Denver - CO, USA)  
*Uric acid and CV and metabolic disease: from the back to the future*
- 07.00 p.m. Welcome cocktail

## Friday, December 2<sup>nd</sup>, 2016 – Morning

### SESSION I - Serum uric acid and gout: from the human evolution to mechanism of disease

- Chairpersons: **C. Borghi** (Bologna, I)  
**F.H. Messerli** (Bern, CH)
- 09.00 a.m. **F. M. Galassi** (Zurich, CH)  
*Uric acid and CV disease: an historical perspective*
- 09.30 a.m. **T. Gibson** (London, UK)  
*Biochemistry of uric acid in clinical perspective*
- 10.00 a.m. **E. E. Kelley** (Morgantown - WV, USA)  
*Manipulating XOR-Derived Product Identity (Uric Acid, ROS and NO) to address metabolic/cardiovascular dysfunction allied to obesity*
- 10.30 a.m. **H. Sakurai** (Tokyo, J)  
*Transporter-centric view of urate (patho)physiology*
- 11.00 a.m. Coffee break

**SESSION II - Serum uric acid, gout  
and cardio-renal disease: the genetic approach**

Chairpersons:	<b>J. Dawson</b> (Glasgow, UK) <b>M. Volpe</b> (Rome, I)
11.30 a.m.	<b>T. R. Merriman</b> (Dunedin, NZ) <i>Genetic aspects of gout</i>
12.00 a.m.	<b>J. Dawson</b> (Glasgow, UK) <i>Genes, uric acid and CV diseases</i>
12.30 p.m.	<b>C. Zoccali</b> (Reggio Calabria, I) <i>The challenge of Mendelian randomization approach</i>
01.00 p.m.	Lunch

**Friday, December 2<sup>nd</sup>, 2016 – Afternoon**

**SESSION III - Gout and cardio-renal co-morbidities**

Chairpersons:	<b>G. Minisola</b> (Rome, I) <b>P. Pauletto</b> (Treviso, I)
02.00 p.m.	<b>L. Punzi</b> (Padua, I) <i>The interaction between gout and other rheumatic diseases: current trends</i>
02.30 p.m.	<b>C. Ferri</b> (L'Aquila, I) <i>The problem of cardio-renal diseases in patients with gout</i>
03.00 p.m.	<b>L. M. Ruilope</b> (Madrid, E) <i>The management of gout in the era of complexity</i>
03.30 p.m.	Coffee break

## SESSION IV - Serum uric acid and hypertension

Chairpersons:	<b>G. Mancia</b> (Milan, I) <b>A. J. Manolis</b> (Athens, GR)
04.00 p.m.	<b>D. I. Feig</b> (Birmingham - AL, USA) <i>Uric acid and hypertensive disease at early age</i>
04.30 p.m.	<b>G. Grassi</b> (Milan, I) <i>Effects of serum uric acid on blood pressure lowering treatment</i>
05.00 p.m.	<b>S. Taddei</b> (Pisa, I) <i>The effect of antihypertensive drugs on serum uric acid: does it matter?</i>
05.30 p.m.	<b>MAIN LECTURE</b> <b>Introduction: M. H. Alderman</b> (New York - NY, USA) <b>A. Lerman</b> (Rochester - MN, USA) <i>Serum uric acid and the endothelium: is this the battlefield?</i>
06.00 p.m.	End of the session

## Saturday, December 3<sup>rd</sup>, 2016 – Morning


### SESSION V - Uric acid and cardiovascular diseases beyond hypertension

Chairpersons:	<b>P. G. Camici</b> (Milan, I) <b>L. M. Ruilope</b> (Madrid, E)
08.30 a.m.	<b>L. O. Lerman</b> (Rochester - MN, USA) <i>Hyperuricemia and CV disease: the role of renal impairment</i>
09.00 a.m.	<b>W. Doehner</b> (Berlin, D) <i>Complexity of heart failure: the emerging role of hyperuricemia</i>
09.30 a.m.	<b>A. J. Manolis</b> (Athens, GR) <i>Serum uric acid and atrial fibrillation: update on epidemiology and disease mechanism</i>
10.00 a.m.	<b>C. Borghi</b> (Bologna, I) <i>Hyperuricemia and new onset diabetes/metabolic syndrome</i>
10.30 a.m.	Coffee break



## Session VI - Open issues in the management of hyperuricemia

Chairpersons:	<b>E. Agabiti Rosei</b> (Brescia, I) <b>A. Stack</b> (Limerick, IRL)
11.00 a.m.	<b>G. Desideri</b> (L'Aquila, I) <i>Is there any "J-shaped" curve for serum uric acid?</i>
11.30 a.m.	<b>Y. Shibagaki</b> (Sugao, J) <i>Renal protective effects of urate lowering drugs</i>
12.00 a.m.	<b>R. Pontremoli</b> (Genoa, I) <i>Does urate lowering treatment reduces CV risk in renal patients?</i>
12.30 p.m.	<b>T. MacDonald</b> (Dundee, UK) <i>Cardiovascular effects of urate lowering treatment: the role of drugs</i>
01.00 p.m.	<b>J. T. Kielstein</b> (Braunschweig, D) <i>The preventive role of urate lowering treatment: who should be treated?</i>
01.30 p.m.	Concluding Remarks
01.45 p.m.	Lunch



## GENERAL INFORMATION

<b>Meeting venue</b>	The venue of the Symposium will be Salone del Podestà, Palazzo Re Enzo – Piazza del Nettuno, 1 - Bologna (Italy)
<b>Secretariat during the Meeting</b>	The Secretariat will be open at the following times: Thursday, December 1 <sup>st</sup> , from 04.00 p.m. to 07.00 p.m. Friday, December 2 <sup>nd</sup> , from 08.00 a.m. to 06.00 p.m. Saturday, December 3 <sup>rd</sup> , from 08.00 a.m. to 01.30 p.m.
<b>Official language</b>	The official language of the Symposium will be English.
<b>Registration</b>	The Symposium is free to attend.
<b>Technical facilities speakers</b>	Facilities will be available for computer presentations and overhead projections. A slide center with PC (Powerpoint for Windows) will be available to check and preview presentations. It is essential that speakers take their presentations to the slide center at least one hour before the session starts. The slide center will be open at the following times: Thursday, December 1 <sup>st</sup> , from 04.00 p.m. to 07.00 p.m. Friday, December 2 <sup>nd</sup> , from 08.00 a.m. to 06.00 p.m. Saturday, December 3 <sup>rd</sup> , from 08.00 a.m. to 01.30 p.m.
<b>Lunches and coffee breaks</b>	Lunches and coffee breaks will be served at Palazzo Re Enzo.
<b>Abstract book</b>	Participants will receive the Abstract book in the congress kit.
<b>Certificate of attendance</b>	The certificate of attendance will be available, on request, at the Secretariat Desk.

## Italian CME Credits

Italian credits for Italian Physicians have been requested for **December 2<sup>nd</sup> – 3<sup>rd</sup> only.**

Provider Italian CME Credits:

I&C srl: 5387

ID CME ITALIAN CREDITS: 5387 - 168136

CME CREDITS N. 5,5

I&C srl is responsible for the content, the quality and the ethical honesty of the CME activity. The meeting is accredited for the following specialties: Nurse, Pharmacist, Biologist, Physician and Surgeon (Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene). The physicians belonging to other disciplines will not get the credits. The attendance to the meeting is partially on sponsor companies invitation.

METHODOLOGY

Residential.

COURSE OBJECTIVES

Clinical, Diagnostic, Therapy, Treatment Path.


LEARNING TEST

The credits will be obtained by attending both days of the meeting (100% of attendance), by answering correctly to the 75% of the CME test questions and by filling the CME forms delivered at the meeting.

## European CME Credits

EBAC and EACCME credits have been requested for **December 1<sup>st</sup> - 2<sup>nd</sup> - 3<sup>rd</sup>** for the following disciplines:

Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene.





‘URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY’ (Event code: 14792) was granted **10 European CME credits** (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

‘URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), [www.uems.net](http://www.uems.net). ‘URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY’ is designated for a maximum of 10 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

Information on the process to convert EACCME credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

### **EACCME credits**

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.



The event “URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY” is accredited by the European Board for Accreditation in Cardiology (EBAC) for 12 CME credit hours of External CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

**LIST OF SPEAKERS, CHAIRPERSONS AND CO-PRESIDENTS  
OF THE MEETING**

**Enrico AGABITI ROSEI**

Department of Clinical and  
Experimental Sciences  
University of Brescia  
Spedali Civili di Brescia  
Brescia (Italy)

---

**Michael H. ALDERMAN**

Distinguished University  
Professor Emeritus  
Departments of Medicine  
and Population Health  
Albert Einstein College of Medicine  
Bronx, New York - NY (USA)

---

**Ettore AMBROSIONI**

Italian Society of Hypertension  
Bologna (Italy)

---

**Claudio BORGHI**

Department of Medical and Surgical  
Sciences (DIMEC)  
Alma Mater Studiorum University  
of Bologna  
Bologna (Italy)

---

**Paolo G. CAMICI**

Myocardial Diseases Center  
San Raffaele Hospital  
Milan (Italy)

**Jesse DAWSON**

Institute of Cardiovascular  
and Medical Sciences  
University of Glasgow  
Queen Elizabeth University Hospital  
Glasgow (United Kingdom)

---

**Giovambattista DESIDERI**

U.O.C. Geriatrics and Long-term care  
Medical Department ORM  
University of L'Aquila  
L'Aquila (Italy)

---

**Wolfram DOEHNER**

Centre for Stroke Research  
University of Berlin  
Berlin (Germany)

---

**Daniel I. FEIG**

Division of Nephrology  
Children's of Alabama  
University of Alabama  
Birmingham - AL (USA)

---

**Claudio FERRI**

Division of Internal Medicine  
and Nephrology  
School of Internal Medicine  
University of L'Aquila  
San Salvatore Hospital  
Coppito - L'Aquila (Italy)

**Francesco M. GALASSI**

Institute of Evolutionary Medicine  
Faculty of Medicine  
University of Zurich  
Zurich (Switzerland)

---

**Terence GIBSON**

Department of Acute Medicine  
St. Thomas Hospital  
London (United Kingdom)

---

**Guido GRASSI**

Department of Health Sciences  
University of Milano-Bicocca  
Milan (Italy)

---

**Richard J. JOHNSON**

Division of Renal Diseases and  
Hypertension  
University of Colorado  
Anschutz Medical Campus  
Denver - CO (USA)

---

**Eric E. KELLEY**

Department of Physiology  
and Pharmacology  
West Virginia University  
School of Medicine  
Morgantown - WV (USA)

---

**Jan T. KIELSTEIN**

Medical Clinic V  
Nephrology and Hypertension  
Academic Teaching Hospital  
Braunschweig (Germany)

**Amir LERMAN**

Division of Nephrology  
and Hypertension  
Mayo College of Medicine  
Rochester - MN (USA)

---

**Lilach O. LERMAN**

Division of Nephrology and  
Hypertension  
Mayo College of Medicine  
Rochester - MN (USA)

---

**Thomas MACDONALD**

School of Medicine  
University of Dundee  
Dundee (United Kingdom)

---

**Giuseppe MANCIA**

University of Milano-Bicocca  
Milan (Italy)

---

**Athanasios MANOLIS**

Department of Cardiology  
Hospital of Asklepeion  
Athens (Greece)

---

**Tony R. MERRIMAN**

Biochemistry Department  
School of Medical Sciences  
University of Otago  
Dunedin (New Zealand)

---

**Franz H. MESSERLI**

Mount Sinai Icahn School of Medicine  
New York (USA)  
University of Bern (Switzerland)  
Jagie/Ionian University Krakow (Poland)

**Giovanni MINISOLA**

Rheumatology Unit  
San Camillo Hospital  
Rome (Italy)

---

**Paolo PAULETTO**

Department of Internal Medicine  
University Hospital of Treviso  
University of Padua Medical School  
Treviso (Italy)

---

**Roberto PONTREMOLI**

Department of Internal Medicine and  
Medical Specialties  
University of Genoa  
Genoa (Italy)

---

**Leonardo PUNZI**

Rheumatology Unit  
Department of Medicine  
Medical School  
University of Padua  
Padua (Italy)

---

**Luis Miguel RUILOPE**

Hypertension Unit  
Hospital 12 de Octubre  
Madrid (Spain)

---

**Hiroyuki SAKURAI**

Department of Pharmacology and  
Toxicology  
School of Medicine  
Kyorin University  
Tokyo (Japan)

**Yugo SHIBAGAKI**

Department of Internal Medicine  
Division of Nephrology and Hypertension  
Department of Internal Medicine  
St. Marianna University School of Medicine  
Sugao (Japan)

---

**Austin STACK**

Department of Nephrology  
University Hospital Limerick  
Graduate Entry School of Medicine  
University of Limerick  
Limerick (Ireland)

---

**Stefano TADDEI**

Department of Clinical  
and Experimental Medicine  
University of Pisa  
Pisa (Italy)

---

**Massimo VOLPE**

Cardiology Unit  
Department of Cardiothoracic and  
Vascular Science  
Faculty of Medicine and Psychology  
Sapienza University of Roma  
Rome (Italy)

---

**Carmine ZOCCALI**

CNR-IFC  
Clinical Epidemiology of Renal  
Diseases and Hypertension  
Reggio Calabria (Italy)



# - Notes -

A series of horizontal dashed lines for writing notes.

# - Notes -

A series of horizontal dashed lines for writing notes.

